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Abstract
Background: Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede
the development of liver cancer. However, human studies, particularly from prospective settings, are lacking.
Methods: We used a case-control study design nested within a large prospective cohort to assess the association
between circulating levels of anti-lipopolysaccharide (LPS) and anti-flagellin immunoglobulin A (IgA) and G (IgG)
(reflecting long-term exposures to LPS and flagellin, respectively) and risk of hepatocellular carcinoma. A total of 139
men and women diagnosed with hepatocellular carcinoma between 1992 and 2010 were matched to 139 control
subjects. Multivariable rate ratios (RRs), including adjustment for potential confounders, hepatitis B/C positivity, and
degree of liver dysfunction, were calculated with conditional logistic regression.
Results: Antibody response to LPS and flagellin was associated with a statistically significant increase in the risk of
hepatocellular carcinoma (highest vs. lowest quartile: RR = 11.76, 95% confidence interval = 1.70–81.40; Ptrend = 0.021).
This finding did not vary substantially by time from enrollment to diagnosis, and did not change after adjustment for
chronic infection with hepatitis B and C viruses.
Conclusions: These novel findings, based on exposures up to several years prior to diagnosis, support a role
for gut-derived bacterial products in hepatocellular carcinoma development. Further study into the role of gut
barrier failure and exposure to bacterial products in liver diseases is warranted.
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Background
Hepatocellular carcinoma (HCC) has several established
risk factors, namely chronic infection with hepatitis B
and/or C viruses (HBV/HCV), aflatoxin exposure, dia-
betes, obesity, smoking, and high alcohol consumption
[1]. Recent observations from the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort
also show a role for dietary and lifestyle exposures in
HCC development [2–6] and indicate metabolic differ-
ences between cases and controls [7–9]. Other observa-
tions suggest that many of these same factors can
weaken the colonic epithelial barrier function [10–12],
allowing the translocation of toxic bacterial products
such as lipopolysaccharide (LPS; also known as endo-
toxin, an integral part of the outer membrane of Gram-
negative bacterial cell walls) and flagellin (the primary
structural component of flagella). Overabundance of
bacterial LPS from the gut microbiota may trigger
chronic inflammation and higher oxidative stress [13].
Since these bacterial cell components are transported to
the liver through the portal vein, it has been suggested
that they drive the development of metabolic and liver
diseases. In fact, animal data suggest that exposure to
LPS or flagellin can produce liver inflammation, liver
injury, or steatohepatitis [14–16], while human data in-
dicate higher circulating LPS in patients with chronic
liver diseases predisposing to HCC (non-alcoholic fatty
liver disease [NAFLD] and non-alcoholic steatohepatitis
[NASH]) [17–24]. However, despite a probable role of
gut-derived bacterial products in the pathogenesis and
progression of liver disease, no epidemiologic studies to
date have investigated the association between bio-
markers of LPS and flagellin and risk of HCC. In consid-
eration of these points, in a first study of its kind, we
investigate whether prediagnostic serum anti-LPS- and
anti-flagellin-specific immunoglobulin A and G (IgA and
IgG) levels are associated with HCC risk within EPIC, a
large cohort of geographically diverse Western European
populations.
Methods
Study design
EPIC is a multicenter prospective cohort study designed
to investigate the association between lifestyle and envir-
onmental factors and cancer incidence. The rationale
and study design are described in detail elsewhere [25].
The study subjects were recruited from the general
population, except for Utrecht and Florence (women at-
tending breast cancer screening), the Oxford “Health
conscious” subcohort (half are vegetarian), and subsam-
ples of the Italian and Spanish cohorts (blood donors).
Lifestyle data were collected from approximately 520,000
men and women aged 20–85 years enrolled between
1992 and 2000 in 23 centers throughout 10 European
countries. At recruitment, blood samples were collected
from most participants and are stored at the International
Agency for Research on Cancer (IARC, Lyon, France) in –
196 °C liquid nitrogen for all countries except Denmark
(–150 °C, nitrogen vapor) and Sweden (–80 °C, freezers).
Approval for this study was obtained from the IARC
Ethics Committee (Lyon, France) as well as from partici-
pating EPIC centers.
Follow-up for cancer incidence
Cancer incidence was determined through record link-
age with population-based regional cancer registries
(Denmark, Italy, the Netherlands, Norway, Spain,
Sweden, and the UK; complete up to December 2008)
or via a combination of methods (health insurance re-
cords, contacts with cancer/pathology registries, active
follow-up through study subjects and next of kin;
France, Germany, Greece; complete until June 2010).
The nested case-control study
Ascertainment of case patients and selection of controls
HCC was defined as first incident tumor in the liver
(C22.0 as per the 10th Revision of the International Stat-
istical Classification of Diseases, Injury and Causes of
Death [ICD-10]). For each identified case, the histology,
the methods used to diagnose the cancer, and α-
fetoprotein levels were reviewed to exclude metastatic
cases or other types of liver cancers as described previ-
ously [2]. During the period between recruitment and
2010, a total of 204 HCC cases were identified. Sixty-five
cases had no available serum samples (including 21 cases
diagnosed after 2006 in Malmö, Sweden, and Denmark
and excluded for administrative reasons and lack of
biosample availability) and were not included in the ana-
lysis; however, they did not differ by lifestyle and demo-
graphic characteristics from cases with available serum
samples. For each case, one control was selected by inci-
dence density sampling from all cohort members alive
and free of cancer (except non-melanoma skin cancer),
and matched by age at blood collection (±1 year), sex,
center, date (±2 months)/hour (±3 h) of blood collection,
fasting status at blood collection (<3/3–6/>6 h); add-
itionally among women, menopausal status (pre-/peri-/
postmenopausal) and hormone replacement therapy use
at blood collection (yes/no). The final sample size in-
cluded 139 HCC cases and 139 matched controls.
Laboratory biomarker measures for serum anti-LPS- and
anti-flagellin-specific Ig levels
Serum anti-LPS- and anti-flagellin-specific IgA and IgG
levels were quantitated by enzyme-linked immunosorb-
ent assay (ELISA) at Georgia State University (Atlanta,
GA, USA), as previously described [26–28]. Briefly,
ELISA plates (Costar™) were coated overnight with
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purified laboratory-made flagellin (100 ng/well; prepared
from Salmonella typhimurium, strain SL 3201 fljB-/- as
previously described [29]) or purified Escherichia coli
LPS (2 μg/well; from E. coli 0128: B12, Sigma, Catalog
No. 2887) in 9.6 pH bicarbonate buffer. Serum samples
from cases and controls diluted 1:200 were applied to
wells coated with flagellin or LPS. After incubation and
washing, the wells were incubated either with anti-IgG
coupled to horseradish peroxidase (GE, Catalog No.
375112) or, in the case of IgA-specific antibodies, with
horseradish peroxidase-conjugated anti-IgA (KPL,
Catalog No. 14-10-01). Using the established platform,
specificity of anti-flagellin/LPS Igs is observed when the
signal is extremely low when using serum from germ-
free mice and completely abolished using serum from
RAG-1 knockout mice and germ-free mice on an elem-
ental diet. The specificity of the anti-human IgA and
anti-human IgG is in accordance with manufacturer's
specifications. Quantitation of total immunoglobulins
was performed using the colorimetric peroxidase sub-
strate tetramethylbenzidine (TMB), and the optical
density (OD) was read at 450 nm and 540 nm (the dif-
ference was taken to compensate for optical interfer-
ence from the plate) with an ELISA plate reader. Data
are reported as OD corrected by subtracting back-
ground (determined by readings in blank samples) and
are normalized to each plate’s control sample, which
was prepared in bulk, aliquoted, frozen, and thawed
daily as used. Standardization was performed using
preparations of known concentrations of IgA and IgG.
Matched case-control pairs were handled identically
and assayed in the same batch in a blinded fashion. A
very low coefficient of variation (CV <5%) between
duplicates based on previous assays [30] permitted
singleton sample analysis. Based on three positive con-
trol samples included in each plate, mean inter-assay
CVs were 2.2%, 2.5%, 3.4%, and 4.8% for anti-LPS IgG,
anti-flagellin IgA, anti-LPS IgA, and anti-flagellin IgG,
respectively. The between-batch CVs were 9.3%, 12.7%,
16.2%, and 11.3% for anti-flagellin IgA, anti-flagellin
IgG, anti-LPS IgA, and anti-LPS IgG, respectively.
Laboratory assays of HBV/HCV status, biomarkers of liver
injury, and hsCRP
The present analysis included existing biomarker data
for the same set of cases and matched controls [2, 7, 9].
For a total of 100 of the HCC cases (those diagnosed
before 2006) and their matched controls, existing data
were available for HBV/HCV seropositivity (ARCHI-
TECT HBsAg and anti-HCVchemiluminescent microparticle
immunoassays; Abbott Diagnostics, France) and biomarkers
of hepatic injury (alanine aminotransferase [ALT], aspartate
aminotransferase [AST], gamma-glutamyltransferase [GGT],
liver-specific alkaline phosphatase [AP], albumin, total
bilirubin, and total protein; ARCHITECT c Systems™;
Abbott Diagnostics) [2]. We created the liver damage
score by summarizing the number of abnormal values
for six liver function tests (ALT > 55 U/L, AST > 34 U/
L, GGT men >64 U/L, GGT women >36 U/L, AP >150
U/L, albumin <35 g/L, total bilirubin >20.5 μmol/L;
cut-points were provided by the laboratory and were
based on assay specifications; range from 0 to 6).
Serum amino acids were measured for all 139 cases
and 139 matched controls using the Biocrates Abso-
luteIDQ p150 mass spectrometry kit (Biocrates Life Sci-
ence AG, Innsbruck, Austria) on a QTRAP mass
spectrometer (IARC, Lyon, France) [9]. Fischer’s ratio
was calculated as the molar ratio of branched-chain
amino acids (leucine + valine + isoleucine) to aromatic
amino acids ([phenylalanine + tyrosine + histidine +
tryptophan] or [phenylalanine + tyrosine]) and was used
as an indicator of hepatic functional reserve and severity
of liver dysfunction [31, 32]. High-sensitivity C-reactive
protein (hsCRP) was measured using a high-sensitivity
assay on a Turbidimetric Modular system (Roche,
Mannheim, Germany) [7].
Statistical analyses
No transformations were used for all biomarkers
because they were normally distributed. Differences in
concentrations of biomarkers among the controls by
baseline characteristics were examined by analysis of
variance. P values for tests of trend (for ordinal vari-
ables) or of heterogeneity were reported. Four condi-
tional logistic models were used to assess the strengths
of association (incidence rate ratio [IRR] as estimated by
odds ratio [OR] [33] with 95% confidence interval (CI)
and tests for trend): (1) with matching factors only, (2)
with adjustment for potential confounders (smoking
status [never, former, current], body mass index [con-
tinuous], baseline alcohol intake [continuous], coffee in-
take [continuous], lifetime alcohol drinking pattern
[always heavy, periodically heavy, former heavy, never
heavy, former light, light, and never drinkers], physical
activity [active, moderately active, moderately inactive,
inactive], and level of education [none, primary school,
secondary school, more than secondary school, not
specified]), and (3) with additional adjustment for
Fischer’s ratio (molar ratio of branched-chain amino
acids [leucine + valine + isoleucine] to aromatic amino
acids [phenylalanine + tyrosine + histidine + tryptophan]);
inversely related to severity of liver dysfunction, with
lower values of the ratio indicating a more severe liver
dysfunction [31, 32]. Serum anti-LPS and anti-flagellin
immunoglobulin levels were included individually and in
the following logical combinations in models as continu-
ous (per unit increase; approximately equal to 1 standard
deviation for each individual biomarker) and as
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categorical variables, with quartile cut-points based on the
distribution in the control subjects: (1) total anti-LPS =
anti-LPS IgG + anti-LPS IgA (total exposure to LPS); (2)
total anti-flagellin = anti-flagellin IgG + anti-flagellin IgA
(total exposure to flagellin); (3) anti-LPS and anti-flagellin
IgG = anti-LPS IgG + anti-flagellin IgG (all IgGs, indicating
possible systemic response to endotoxins [34]); (4) anti-
LPS and anti-flagellin IgA = anti-LPS IgA + anti-flagellin
IgA (all IgAs, indicating possible mucosal response to
endotoxins [34]); (5) anti-LPS flagellin = anti-LPS IgG +
anti-flagellin IgG + anti-LPS IgA + anti-flagellin IgA (total
exposure to LPS and flagellin). To test dose responses,
trend variables were assigned the median values for each
quartile of biomarker.
To partly control for potential pre-existing liver dys-
function, in the multivariable model, we also performed
additional adjustment for and stratification by HBV/
HCV status and “liver damage score” by summarizing
the number of abnormal values for six liver function
tests (categorized as 0 = no liver injury, 1–2 = possible
minor injury, ≥3 = possible injury; see Additional file 1:
Table S1 and Table 4 footnote).
Effect modification on the multiplicative scale for po-
tential biologically plausible effect modifying variables
(sex, age at diagnosis, body mass index [BMI, normal vs.
overweight/obese], prevalent type 2 diabetes [yes vs. no;
data available for a subset of subjects only], smoking
[never vs. former/current], lifetime alcohol drinking pat-
tern [ever heavy vs. light/never]) was tested by including
interaction terms formed by the product of modifying
variable categories and the value of categories of expos-
ure of interest. The statistical significance of interactions
was assessed using likelihood ratio tests based on the
models with and without the interaction terms.
All statistical tests were two-sided, and P values <0.05
were considered statistically significant. Analyses were
conducted using the SAS version 9.2 (SAS Institute,
Cary, NC, USA) statistical package.
Results
Baseline characteristics of participants
HCC cases were diagnosed, on average, 6 years (standard
deviation = 3.4) after blood collection and had a greater
proportion of current smokers and a greater prevalence
of diabetes than controls (Table 1). The mean serum
concentration of total anti-LPS and anti-flagellin Igs was
higher in HCC cases vs. controls (8.08 vs. 6.86, P <
0.001). No difference in total anti-LPS and anti-flagellin
Ig levels by HBV/HCV status was observed for both
HCC cases (P = 0.379) and controls (P = 0.722). The
Fischer ratio was lower in HCC cases vs. controls (1.33
vs. 1.53, P < 0.001) and, among cases, moderately in-
versely correlated with total anti-LPS and anti-flagellin
Igs (r = –0.28, P < 0.001). Among cases, having potential
liver dysfunction as indicated by a liver damage score
value ≥3 was associated with higher levels of total anti-
LPS and anti-flagellin Igs among cases (P < 0.001 com-
pared to cases with a liver damage score value of 0).
Lifestyle and dietary factors associated with anti-LPS and
anti-flagellin Igs in controls
Among controls, concentrations of biomarkers did not dif-
fer statistically significantly by sex, age at blood collection
(Table 2), and other factors (Additional file 1: Table S2). A
higher BMI was associated with higher concentrations of
anti-LPS Igs (P = 0.02), anti-LPS and anti-flagellin
IgGs (P = 0.02), and total anti-LPS and anti-flagellin
(P = 0.04). Similar patterns were observed for waist-
to-hip ratio, a measure of central adiposity, and CRP,
a biomarker of chronic systemic inflammation, al-
though they were not statistically significant.
Associations of serum anti-LPS and anti-flagellin Igs with
risk of HCC
The associations between LPS and flagellin biomarkers
with risk of HCC are presented in Table 3 (for logical com-
bination of biomarkers) and Additional file 1: Table S3 (for
individual biomarkers). All analysis models showed a sta-
tistically significant positive association between high anti-
LPS and anti-flagellin Ig levels and HCC risk (for total
anti-LPS and anti-flagellin Igs, highest vs. lowest quartiles,
matching factors model: IRR = 8.72, 95% CI: 2.78–27.29;
most adjusted multivariable model with Fischer’s ratio:
IRR = 11.76, 95% CI: 1.70–81.40, Ptrend = 0.021).
Effect modifications and sensitivity analyses
For all variables tested, no statistically significant ef-
fect modification were observed (all P >0.26), except
for sex, which demonstrated as borderline non-
significant (Table 4; P values for interaction by sex
≥0.03, see the footnotes). However, the number of
women in the study was much smaller compared to
the number of men. We also checked the consistency
of our results after the exclusion of the cases diag-
nosed during the first 2 and 4 years of follow-up to
exclude possible reverse causation, since the partici-
pants might have modified their diet and/or lifestyle
before enrollment due to prediagnostic symptoms.
The estimates did not change considerably after
these exclusions or in analyses stratified by follow-up
time. The magnitude of the effect estimates did not
change substantially after excluding persons with
positive HBV/HCV status (data not shown) or by
further adjustment for HBV/HCV status and liver
damage score (Table 4).
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Discussion
In this case-control study nested within a large prospect-
ive cohort, we observed a statistically significant positive
association between prediagnostic serum concentrations
of anti-LPS and anti-flagellin Igs and risk of HCC. The
strength of the association did not vary substantially by
time from enrollment to diagnosis and was only mod-
estly impacted by adjustment for various lifestyle factors
and markers reflecting pre-existing liver damage. These
findings provide the first prospective epidemiologic evi-
dence on the topic and add to the existing experimental
data showing that weakened gut barrier function and
subsequent exposure to bacterial products may promote
hepatocarcinogenesis [13, 35].
Higher circulating levels of anti-LPS and anti-flagellin
Igs are thought to be indicative of chronic exposure to
Table 1 Baseline characteristics of incident HCC cases and matched control subjects within the European Prospective Investigation
into Cancer and Nutrition (EPIC) study from 1992 to 2010
Characteristic Case subjects (N = 139) Matched control subjects (N = 139)a P value
Men (%) 70.5 70.5 –e
Age at blood collection (y), mean (SD) 60.0 (7.3) 60.0 (7.3) –e
Follow-up from blood collection (y), mean (SD) 6.0 (3.4) – –
Smoking status (%) 0.002
Never smoker 29.7 43.5
Former smoker 30.4 36.2
Current smoker 39.1 19.6
BMI (kg/m2), mean (SD) 28.4 (4.7) 27.3 (4.2) 0.035
Physical activity (%) 0.652
Inactive 7.3 10.9
Moderately inactive 36.2 31.2
Moderately active 46.4 48.6
Active 10.1 9.4
No. with prevalent diabetes (%) 13.0 7.3 0.455
HBV or HCV positive (%)b 35.6 3.0 <0.001
HBV positive (%)b 16.8 2.0 <0.001
HCV positive (%)b 21.8 2.0 <0.001
Liver damage score (%)b
0 29.0 83.2 <0.001
1–2 31.0 16.8
≥3 40.0 0
Baseline blood biomarkers, mean (SD)
Anti-LPS IgG + IgA 4.27 (1.38) 3.64 (1.32) <0.001
Anti-flagellin IgG + IgA 3.81 (1.34) 3.22 (1.17) <0.001
Anti-LPS IgG + anti-flagellin IgG 3.62 (1.31) 3.19 (1.19) 0.005
Anti-LPS IgA + anti-flagellin IgA 4.46 (1.57) 3.67 (1.40) <0.001
Anti-LPS IgG + IgA + anti-flagellin IgG + IgA 8.08 (2.59) 6.86 (2.34) <0.001
Fischer's ratioc 1.33 (0.26) 1.53 (0.24) <0.001
C-reactive protein (mg/L)d 2.8 (3.0) 2.0 (2.2) 0.006
From the following recruitment centers, number of HCC cases: Denmark (N = 21), Germany (N = 31), Greece (N = 16), Italy (N = 28), Spain (N = 11), Sweden (N = 13),
the Netherlands (N = 4), United Kingdom (N = 15). No eligible case patients were identified in the cohorts of France and Norway, which include women only
aControl subjects had to be alive as of the time of diagnosis of the corresponding case patients and were matched with case patients for study center, sex, age at
the time of blood collection (±12 months), date of blood collection (±2 months), and time of day of blood collection (±3 h). Women were further matched by
menopausal status (pre-, post-, or perimenopausal) and use of exogenous hormones (oral contraceptives for premenopausal women and hormone replacement
therapy for postmenopausal women) at time of blood collection
bAvailable for 100 cases and 100 controls
cCalculated as the molar ratio of branched-chain amino acids (leucine, valine, isoleucine) to aromatic amino acids (phenylalanine, tyrosine, histidine, tryptophan),
an indicator of hepatic functional reserve and the severity of liver dysfunction. Geometric means (SD)
dGeometric means and SDs, available for 100 cases and 100 controls
eMatching factor
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bacterial products LPS and flagellin, which can elicit
innate immune and inflammatory responses [36]. High
exposure of the liver to these microbial products could be
due to their translocation through the disrupted gut bar-
rier, which could be a result of intestinal inflammation,
chronic alcohol abuse, early phase hepatic injury, or diet-
ary and/or lifestyle factors [24, 37, 38]. In fact, data from
animal studies support an important role for gut micro-
biota in liver health and disease [13, 39]. Furthermore, pa-
tients with NAFLD and NASH, liver diseases that often
precede HCC, demonstrate elevated circulating endotoxin
levels, LPS, LPS-binding protein, and anti-LPS antibodies
[17–24]. It is plausible that dietary and lifestyle factors as-
sociated with higher risk of cancer development, such as
components of Western-type diets, instigate microbiome
changes, favoring the relative abundance of Gram-
negative bacteria, and thus leading to increased exposure
to LPS. For example, studies in mice show that diets high
in fructose or fat can alter gut barrier function, inducing
endotoxemia and the development of liver steatosis [11,
40]. Similar observations have been made in humans [21]
and for other factors such as obesity [12, 36, 41]. Although
Table 3 Incidence rate ratios (IRR) and 95% confidence intervals of hepatocellular carcinoma according to categories of and per 1
unit increase in serum anti-LPS and anti-flagellin immunoglobulin levels, EPIC study, 1992–2010
Biomarker IRR (95% CI) OR per ↑1 unit
Q1 Q2 Q3 Q4 P trend
Anti-LPS IgG + IgA, n case/control 20/35 25/34 35/35 59/35
Matching factorsa Ref. 1.34 (0.61–2.98) 2.74 (1.13–6.65) 11.17 (3.46–36.00) <0.0001 2.19 (1.59–3.03)
Multivariableb Ref. 1.64 (0.56–4.83) 2.52 (0.76–8.39) 17.16 (3.52–83.50) 0.001 2.58 (1.65–4.03)
+ dietary factorsc Ref. 1.65 (0.54–5.04) 2.67 (0.77–9.31) 20.06 (3.88–103.0) 0.001 2.68 (1.69–4.23)
+ Fischer’s ratiod Ref. 2.52 (0.70–9.08) 2.17 (0.55–8.63) 13.65 (1.91–97.80) 0.017 2.05 (1.25–3.36)
Anti-Flagellin IgG + IgA,
n case/control
22/34 25/36 37/35 55/34
Matching factorsa Ref. 1.09 (0.5–2.38) 2.35 (1.03–5.37) 7.11 (2.46–20.55) <0.0001 2.18 (1.56–3.06)
Multivariableb Ref. 1.05 (0.37–2.93) 2.87 (1.00–8.20) 7.78 (2.19–27.57) 0.001 2.31 (1.51–3.54)
+ dietary factorsc Ref. 1.21 (0.40–3.59) 3.07 (1.05–9.01) 6.72 (1.88–24.02) 0.003 2.25 (1.47–3.47)
+ Fischer’s ratiod Ref. 1.52 (0.43–5.37) 4.37 (1.21–15.84) 3.59 (0.79–16.35) 0.025 1.80 (1.12–2.90)
Anti-LPS IgG + Anti-Flagellin IgG,
n case/control
24/34 29/36 40/34 46/35
Matching factorsa Ref. 1.23 (0.58–2.63) 2.11 (0.99–4.52) 4.08 (1.43–11.64) 0.006 2.02 (1.43–2.85)
Multivariableb Ref. 1.40 (0.53–3.68) 2.92 (1.06–8.06) 5.80 (1.46–23.02) 0.007 2.47 (1.56–3.91)
+ dietary factorsc Ref. 1.43 (0.52–3.92) 3.45 (1.18–10.07) 5.37 (1.31–22.10) 0.007 2.57 (1.60–4.12)
+ Fischer’s ratiod Ref. 1.18 (0.39–3.60) 3.89 (1.12–13.58) 2.71 (0.42–17.29) 0.056 1.97 (1.15–3.36)
Anti-LPS IgA + Anti-Flagellin IgA,
n case/control
18/35 27/34 27/35 67/35
Matching factorsa Ref. 2.16 (0.82–5.72) 2.23 (0.85–5.87) 8.47 (3.01–23.86) <0.0001 1.83 (1.43–2.36)
Multivariableb Ref. 4.00 (0.96–16.63) 4.91 (1.15–20.9) 14.22 (3.02–66.90) 0.001 1.99 (1.39–2.86)
+ dietary factorsc Ref. 5.34 (1.21–23.68) 4.73 (1.06–21.16) 14.97 (3.04–73.50) 0.001 1.98 (1.37–2.86)
+ Fischer’s ratiod Ref. 2.65 (0.55–12.84) 4.49 (0.94–21.6) 8.40 (1.64–43.12) 0.009 1.65 (1.11–2.45)
Anti-LPS IgG + IgA + Anti-Flagellin IgG + IgA,
n case/control
23/34 22/35 37/35 57/35
Matching factorsa Ref. 0.97 (0.46–2.08) 2.25 (1.03–4.91) 8.72 (2.78–27.29) <.00001 1.57 (1.31–1.88)
Multivariableb Ref. 1.54 (0.59–4.02) 2.78 (0.94–8.21) 14.01 (2.99–65.60) 0.001 1.72 (1.34–2.21)
+ dietary factorsc Ref. 1.71 (0.63–4.68) 2.78 (0.92–8.35) 13.31 (2.78–63.70) 0.002 1.71 (1.33–2.21)
+ Fischer’s ratiod Ref. 1.75 (0.58–5.27) 2.19 (0.63–7.66) 11.76 (1.70–81.40) 0.021 1.48 (1.13–1.94)
aIRRs and 95% confidence intervals were estimated by conditional logistic regression conditioned on the matching factors
bBase model further adjusted for smoking status (never, former, current), body mass index (continuous), baseline alcohol intake (continuous), coffee intake
(continuous), lifetime alcohol drinking pattern (always heavy, periodically heavy, former heavy, never heavy, former light, light, and never drinker), physical activity
(active, moderately active, moderately inactive, inactive), and level of education (none, primary school, secondary school, more than secondary school,
not specified)
cMultivariable model + baseline dietary fiber (g/day), fish and seafood products (g/day), and total energy (kcal/day)
dMultivariable model + Fischer ratio calculated as the molar ratio of branched-chain amino acids (leucine, valine, isoleucine) to aromatic amino acids (phenylalanine,
tyrosine, histidine, tryptophan), an indicator of hepatic functional reserve and the severity of liver dysfunction
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there is some debate in the current animal literature as to
whether endotoxemia is a cause or consequence of liver
damage [24], it is becoming increasingly clear, as noted
above, that it is involved in the development and progres-
sion of NAFLD [18]. Our results build on this knowledge
to show a possible continued role for endotoxemia in
HCC development.
The most compelling mechanism for this observation
is bacterial dysbiosis (abundance of Gram-negative bac-
teria), breakdown of gut barrier function, and leakage of
bacterial products across the gut lumen. Another poten-
tial mechanism could be increased intestinal LPS ab-
sorption (i.e., preferential incorporation of LPS into
chylomicrons with long-chain dietary fatty acids [42]). Ir-
respective of the mechanisms leading to higher LPS ex-
posure, the link between LPS and increased inflammation
appears convincing [10]. LPS exposure activates the innate
immune system by activating the toll-like receptor 4
(TLR4)-MD2 complex, which in turn through the myeloid
differentiation primary response protein 88 (MYD88)-
dependent and TIR domain-containing adaptor-inducing
IFNβ (TRIF) (or MYD88-independent) pathways, induces
the production of pro-inflammatory cytokines and inter-
feron (IFN)-inducible proteins, respectively [43]. Thus, the
chronic inflammation, oxidative stress, and insulin resist-
ance states of obesity, chronic liver diseases, and, subse-
quently, HCC may be partly related to endotoxemia.
Indeed, there is compelling evidence that obesity might
lead to weakening of the gut barrier function and hence
greater translocation of LPS [10]. Furthermore, both LPS
and flagellin have been shown to induce pro-inflammatory
responses in the gut and liver [29, 44–46]. In our study,
although circulating anti-LPS or anti-flagellin concentra-
tions increased with BMI, multivariable adjustment for
BMI and other perceived confounders (notably alcohol in-
take, alcohol drinking patterns, and smoking) did not at-
tenuate our observed HCC risk associations with any of
the anti-LPS or anti-flagellin biomarkers. Similarly, further
adjustment by hsCRP did not appreciably alter our find-
ings — although our single measure of hsCRP may not be
sufficient to effectively assess local inflammatory states.
Another interesting observation in our study is a poten-
tial sex-specific effect, with a stronger HCC risk observed
in men than in women, although the heterogeneity was
Table 4 Incidence rate ratios (IRRs) and 95% confidence intervals (in parentheses) of hepatocellular carcinoma per 1 unit increase in
serum anti-LPS and anti-flagellin immunoglobulins from analyses stratified according to selected characteristics and sensitivity
analyses, EPIC study, 1992–2010
Model Cases Anti-LPS
IgG + IgA
Anti-flagellin
IgG + IgA
Anti-LPS IgG +
anti-flagellin IgG
Anti-LPS IgA +
anti-flagellin IgA
Anti-LPS IgG + IgA
+ anti-flagellin IgG + IgA
Stratified analyses
By sex
Men 98 5.12 (2.09–12.55) 5.58 (2.11–14.78) 4.93 (2.06–11.79) 2.34 (1.38–3.97) 2.65 (1.58–4.45)
Women 41 1.61 (0.58–4.44) 1.54 (0.54–4.36) 1.21 (0.43–3.41) 1.71 (0.72–4.03) 1.34 (0.75–2.41)
P interaction by sex 0.062 0.059 0.030 0.402 0.055
Cases diagnosed
>2 years since blood collection 117 2.75 (1.62–4.67) 2.04 (1.29–3.21) 2.35 (1.38–4.01) 2.05 (1.33–3.15) 1.68 (1.27–2.23)
>4 years since blood collection 97 4.87 (2.18–10.89) 2.52 (1.4–4.54) 3.70 (1.64–8.34) 2.52 (1.47–4.33) 2.11 (1.41–3.15)
By follow-up timea
< 6 y since blood collection 65 2.45 (1.41–4.26) 2.17 (1.27–3.73) 2.43 (1.36–4.37) 1.89 (1.20–2.95) 1.67 (1.22–2.29)
≥ 6 y since blood collection 74 3.16 (1.65–6.06) 2.57 (1.42–4.64) 2.56 (1.38–4.77) 2.23 (1.36–3.63) 1.82 (1.30–2.56)
Sensitivity analyses
All data, subset with data on
HBV/HCV status
100 2.83 (1.61–4.99) 2.62 (1.43–4.81) 2.88 (1.61–5.15) 1.95 (1.24–3.06) 1.83 (1.32–2.55)
Additionally adjusted for
Liver damage scoreb 100 2.92 (1.02–8.40) 1.76 (0.83–3.72) 2.86 (1.03–7.92) 1.41 (0.75–2.64) 1.56 (0.96–2.51)
HBV/HCV status and liver
damage scoreb
100 3.35 (0.82–13.77) 1.66 (0.62–4.44) 2.35 (0.81–6.79) 1.33 (0.64–2.77) 1.60 (0.83–3.06)
IRRs and 95% confidence intervals were estimated by conditional logistic regression conditioned on the matching factors and adjusted for smoking status (never,
former, current), body mass index (continuous), baseline alcohol intake (continuous), coffee intake (continuous), lifetime alcohol drinking pattern (always heavy,
periodically heavy, former heavy, never heavy, former light, light, and never drinker), physical activity (active, moderately active, moderately inactive, inactive), and
level of education (none, primary school, secondary school, more than secondary school, not specified)
aMean follow-up time among cases (6 years) was used as a cut-point
bSubjects with liver damage score of 0 and 1 were considered to have normal liver function. Liver damage score ranges from 0 to 6, grouped in categories as 0, 1,
≥2 abnormal liver function tests based on the values provided by the laboratory: ALT >55 U/L, AST >34 U/L, GGT men >64 U/L, GGT women >36 U/L, AP >150 U/L,
albumin <35 g/L, total bilirubin >1.2 mg/dL. Available for 100 cases and 100 controls
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not statistically significant, likely because of the small
number of female HCC cases. Nevertheless, the sex differ-
ences observed in our study might be biologically plaus-
ible, as men generally have lower innate and adaptive
immune responses [47, 48], or because the gut micro-
biome may alter sex hormone levels and subsequently
affect inflammation and autoantibody production, as has
been observed in mice [49]. Another animal study has
shown that LPS administration resulted in higher levels of
LPS-binding protein and pro-inflammatory mediators in
male compared to female mice [50]. Interestingly, we pre-
viously observed a similar sex-specific effect for endotoxe-
mia associated with the development of colorectal cancer
[51]. Future studies with larger numbers of women will be
needed to confirm and better understand this potential
effect modification by sex.
The main strength of our study is its prospective de-
sign, which allowed measurement of the biomarkers in
blood samples collected in some cases many years prior
to diagnosis. This implies a greater level of confidence in
the hypothesis that higher LPS exposure and its various
harmful effects are involved in early processes of HCC
development. Nevertheless, higher LPS levels also may
be indicative of a degree of liver dysfunction, since LPS-
binding protein, which binds free circulating LPS, is syn-
thesized in the liver, and individuals with a chronic liver
disease may have altered hepatic endotoxin detoxifica-
tion [52, 53]. Interestingly, the magnitude of our findings
was not influenced by additional statistical adjustment
for markers of liver dysfunction, further strengthening
the argument for an early involvement of endotoxemia
in HCC development. Other advantages of the present
study are identification of HCC cases based on tumor
morphology to ensure the inclusion of only first primary
tumors. Research on HCC etiology is hampered by the
rarity of the tumor, the inaccurate diagnosis and report-
ing of primary tumors since the liver is a major site for
cancer metastases, and by metabolic changes that occur
before cancer diagnosis. Therefore, this prospective
study with long and almost complete follow-up, detailed
information on dietary/lifestyle factors, and biomarkers
measured before cancer diagnosis contributes consider-
ably to our understanding of the role of gut-derived en-
dotoxins in HCC etiology, and possibly HCC risk
prediction. In this regard, our study may be criticized for
its use of apparently healthy control subjects rather than
those with non-HCC chronic liver diseases. But in our
opinion, although the latter group may be informative
for screening strategies targeted at individuals at higher
risk of developing HCC, the former is the most appro-
priate for both our prospective cohort design and for
our primary objective of investigating HCC etiology.
In terms of limitations, our results might be suscep-
tible to confounding, since low LPS and flagellin
immunoglobulin levels could indicate better lifestyle and
health status. We have attempted to account for this
with careful adjustment for relevant lifestyle habits (e.g.,
alcohol intake, smoking status, and diet), but we cannot
discount possible residual confounding. Similarly, we
cannot completely rule out the possibility of reverse
causality due to the long-term nature of HCC develop-
ment. We do not have data on incidence of type 2 dia-
betes and liver diseases (e.g., NAFLD or NASH) or on
exposure to aflatoxins, which is uncommon in Western
Europe [54]. Infections caused by Gram-negative bac-
teria of intestinal origin are common among persons
with cirrhosis, especially those with more severe liver
disease, and in in-hospital settings [55]. However, our
study participants were generally healthy at the time of
blood collection, and adjustments for biomarkers of liver
damage or alcohol intake did not materially change the
findings supporting the hypothesis that the presence of
endotoxemia might be an additional factor contributing
to liver carcinogenesis. In addition, obesity and diabetes,
risk factors for HCC, have been shown to be associated
with changes in the gut barrier function [56–58], which
may contribute to HCC development outside of the
spectrum of cirrhosis. However, a possibility that expos-
ure to LPS may trigger the onset of obesity and insulin
resistance was also suggested in animal models [59]. Fi-
nally, our sample size was relatively small, especially for
assessing potential effect modifiers, and liver enzyme
levels and HBV/HCV status were only available for 100
cases and 100 controls. Nevertheless, this is the largest
prospective study to date on HCC etiology in Western
European populations.
Conclusions
In summary, the findings from this prospective study are
in line with the hypothesis that higher exposure to gut-
derived endotoxins (due to impaired gut barrier func-
tion, lifestyle, or altered gut microbiome) is associated
with higher risk of HCC.
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